Insight Molecular Diagnostics Inc.
IMDX- Exchange
- Nasdaq
- Industry
- In Vitro & In Vivo Diagnostic Substances
- SEC CIK
- 0001642380
No open-market purchases or sales by Insight Molecular Diagnostics Inc. insiders were filed in the last 90 days; 40 institutions reported holding it in 13F filings for Q2 2026, worth $108.9M in total; no superinvestor holds it.
Key figures
- Market capClose on Nov 9, 2026
- $81.8M
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, −1 vs. previous quarter
- 40
- 13F valueReported value at the end of Q2 2026
- $108.9M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- $4.05M
- +115.6% year over year
- Net income, FY2025
- -$50.2M
- No comparable prior period
- Free cash flow, FY2025
- -$25.4M
- No comparable prior period
- Revenue, Q2 FY2026
- $239.0K
- −53.9% year over year
Revenue flow, FY2025
Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.
Net loss for FY2025: $50.2M (1238.5% of revenue).
Short interest
See short dataFrom FINRA, settlement date Oct 15, 2026.
- Short interest
- 949.5K
- Shares sold short
- Change
- −23.5K
- −2.4% vs. previous
- Days to cover
- 3.25
- At average daily volume
Superinvestors holding IMDX, Q2 2026
Go to the superinvestors tabNo superinvestor reported holding IMDX at the end of Q2 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Insight Molecular Diagnostics Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Apr 27, 2026 (view filing)7:08 PM ET | Apr 23-27 | 4 days | Broadwood Partners, L.P. and 2 others10% Owner | PPurchaseCommon Stock, no par value | +570.2K | $3.56 | +$2.03M | +4.7%12.7M after | 3 lots |
| Apr 27, 2026 (view filing)7:08 PM ET | Apr 23-27 | 4 days | Broadwood Partners, L.P. and 2 others10% Owner | PPurchaseCommon Stock, no par value | 0 | – | $0 | 0.0%12.7M after | 3 lots |
| Apr 20, 2026 (view filing)7:24 PM ET | Apr 16-20 | 4 days | Broadwood Partners, L.P. and 2 others10% Owner | PPurchaseCommon Stock, no par value | +182.9K | $3.57 | +$652.9K | +1.5%12.1M after | 3 lots |
| Apr 20, 2026 (view filing)7:24 PM ET | Apr 16-20 | 4 days | Broadwood Partners, L.P. and 2 others10% Owner | PPurchaseCommon Stock, no par value | 0 | – | $0 | 0.0%12.1M after | 3 lots |
| Feb 12, 2026 (view filing)7:49 PM ET | Feb 10 | 2 days | Broadwood Partners, L.P. and 2 others10% Owner | PPurchaseCommon Stock, no par value | +521.7K | $5.75 | +$3.00M | +4.6%11.9M after | |
| Feb 12, 2026 (view filing)7:49 PM ET | Feb 10 | 2 days | Broadwood Partners, L.P. and 2 others10% Owner | PPurchaseCommon Stock, no par value | 0 | – | $0 | 0.0%11.9M after | |
| Feb 11, 2025 (view filing) | Feb 7 | 4 days | James Andrea S.Chief Financial Officer | PPurchaseCommon Stock, no par value | +97.6K | $2.05 | +$200.0K | +181.8%151.2K after | |
| Feb 11, 2025 (view filing) | Feb 7 | 4 days | Smith Patrick W10% Owner | PPurchaseCommon Stock, no par value | +1.08M | $2.05 | +$2.21M | +60.0%2.87M after | |
| Feb 10, 2025 (view filing)8:43 PM ET | Feb 6 | 4 days | Broadwood Partners, L.P. and 2 others10% Owner | PPurchaseCommon Stock, no par value | +5.17M | $2.05 | +$10.6M | +82.7%11.4M after | 2 lots |
| Feb 10, 2025 (view filing)8:43 PM ET | Feb 6 | 4 days | Broadwood Partners, L.P. and 2 others10% Owner | PPurchaseCommon Stock, no par value | 0 | – | $0 | 0.0%11.4M after | 2 lots |
Top 10 13F holders, Q2 2026
See all 40 holdersThe largest institutional positions in Insight Molecular Diagnostics Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Broadwood Capital Inc | 12,684,884 | $74.8M | 3.91% | +753,045+6.3% | Added |
| AWM Investment Company, Inc. | 2,836,692 | $16.7M | 1.45% | +30,436+1.1% | Added |
| Vanguard Capital Management LLC | 735,847 | $4.34M | 0.00% | +198,686+37.0% | Added |
| Pura Vida Investments, LLC | 484,845 | $2.86M | 7.73% | −462,289−48.8% | Reduced |
| Family Office Research LLC | 368,849 | $2.18M | 0.82% | +241,583+189.8% | Added |
| Geode Capital Management, LLC | 256,903 | $1.52M | 0.00% | −5,150−2.0% | Reduced |
| FNY Investment Advisers, LLC | 182,561 | $1.08M | 0.39% | −64,860−26.2% | Reduced |
| Jane Street Group, LLC | 157,682 | $930.3K | 0.00% | +157,682 | New |
| BlackRock, Inc. | 150,521 | $888.1K | 0.00% | +15,176+11.2% | Added |
| Vanguard Fiduciary Trust Co | 124,576 | $735.0K | 0.00% | −8,015−6.0% | Reduced |
Holders of 5% or more of IMDX
See all 4 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Insight Molecular Diagnostics Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Broadwood Partners, L.P. | 13D/A | 39.70%12.8M shares | +2.30 ppfrom 37.40% | Jan 22, 202110 filings | Apr 27, 2026 | SEC |
| Smith Patrick W | 13G/A | 10.50%1.77M shares | – | Oct 9, 20243 filings | Dec 27, 2024 | SEC |
| AWM Investment Company, Inc. | 13G/A | 10.00%2.86M shares | +2.50 ppfrom 7.50% | Feb 14, 20234 filings | May 9, 2025 | SEC |
| Bio-Rad Laboratories, Inc. | 13G/A | 9.70%2.76M shares | – | Apr 22, 20243 filings | Mar 4, 2025 | SEC |